Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, Kanters S, Deighton K, Hatswell A, Ma L, Limbrick-Oldfield EH, Snider JT, Wade SW, Riberio MT, Radford J, Beygi S, Gribben J. Ghione P, et al. Among authors: beygi s. Haematologica. 2023 Mar 1;108(3):822-832. doi: 10.3324/haematol.2022.281421. Haematologica. 2023. PMID: 36263843 Free PMC article.
Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
Mou E, Falchi L, Sundaram V, Abramson JS, Balassanian R, Beygi S, Fitzpatrick MJ, Frank AK, Gupta S, Lin O, Reed JR, Long SR, Ly A, Menke JR, Reed DR, Ruiz-Cordero R, Volaric AK, Xie Y, Wang L, Wen KW, Zadeh SL, Natkunam Y, Cheung MC, Gratzinger D; Cyto-Heme Institutional Collaborative (CHIC) consortium. Mou E, et al. Among authors: beygi s. Leuk Lymphoma. 2021 Dec;62(12):2864-2872. doi: 10.1080/10428194.2021.1941936. Epub 2021 Jun 26. Leuk Lymphoma. 2021. PMID: 34176413
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity.
Shree T, Shankar V, Lohmeyer JJK, Czerwinski DK, Schroers-Martin JG, Rodriguez GM, Beygi S, Kanegai AM, Corbelli KS, Gabriel E, Kurtz DM, Khodadoust MS, Gupta NK, Maeda LS, Advani RH, Alizadeh AA, Levy R. Shree T, et al. Among authors: beygi s. Blood Cancer Discov. 2022 Mar 1;3(2):95-102. doi: 10.1158/2643-3230.BCD-21-0222. Blood Cancer Discov. 2022. PMID: 35015688 Free PMC article.
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Beygi S, Fernandez-Pol S, Duran G, Wang EB, Stehr H, Zehnder JL, Ramchurren N, Fling SP, Cheever MA, Weng WK, Kim YH, Khodadoust MS. Beygi S, et al. Blood Adv. 2021 Feb 9;5(3):771-774. doi: 10.1182/bloodadvances.2020002371. Blood Adv. 2021. PMID: 33560388 Free PMC article.
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribiero MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. Ghione P, et al. Among authors: beygi s. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):e191-e195.e6. doi: 10.1016/j.clml.2024.01.011. Epub 2024 Jan 24. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38365528
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Neelapu SS, et al. Among authors: beygi s. Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. Blood. 2024. PMID: 37879047 Free PMC article.
26 results